Indeed, previous molecular studies in cellular and murine models of SMA have reported the disruption of skeletal muscle actin-cytoskeleton signaling pathways, the upregulation of the Acta1 gene, and the dysregulation of the RhoA pathway [14,26]. The gene discussed is ACTA1; the disease is proximal spinal muscular atrophy.